which glp 1 drugs are approved for obesity Indications GLP-1/GIP RA Summary Sheet and Beyond! Upcoming wave of hormone-based therapies
Description
Accessed February 5, 2020
PMID 37531876
One large study found that semaglutide use was associated with improved joint outcomes, raising the possibility of a disease-modifying effect
The SURMOUNT-1 trial specifically noted that participants with a BMI of 35 or higher who received the 15mg tirzepatide dose lost an average of 26.5% of their body weight, substantially higher than the overall trial average
Kuhre RE, Ghiasi SM, Adriaenssens AE, et al
